Document is current
Any future updates will be listed below
-
Authors
Cotto-Rios, Xiomaris M. https://orcid.org/0000-0003-0922-1857
Agianian, Bogos https://orcid.org/0000-0003-1295-6846
Gitego, Nadege
Zacharioudakis, Emmanouil
Giricz, Orsi https://orcid.org/0000-0002-1328-3682
Wu, Yang
Zou, Yiyu
Verma, Amit
Poulikakos, Poulikos I.
Gavathiotis, Evripidis https://orcid.org/0000-0001-6319-8331
-
Funding
Funding for this research was provided by:
Melanoma Research Alliance
Irma T. Hirschl Trust
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA238229, R01CA204314, P30CA013330)
American Cancer Society (PF-16-097-CDD)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (T32 AG 23475)
- License Information
-
More Information
Article History
Received: 4 January 2020
Accepted: 5 August 2020
First Online: 1 September 2020
Competing interests
: E.G. and B.A. are inventors to US patent applications no. 62/810,056 and no. 62/810,799 filled by Albert Einstein College of Medicine that cover compounds and compositions to treat cancer related to this manuscript. E.G. has ownership interest in Stelexis Therapeutics, Selphagy Therapeutics, Aspida Therapeutics, and is a consultant/advisory board member for Stelexis Therapeutics, Selphagy Therapeutics, and Life Biosciences. None of the above companies have financial interest in this study or sponsored this research. No competing interests were disclosed by the other authors.
